A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(2 sites)
United States
Memorial Sloan Kettering Westchester, Harrison, New York Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York Last updated February 2026